English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Programmed cell death protein 1 (PD-1) and its ligand PDL1/L2 have recently attracted attention from researchers. Monoclonal antibodies targeting PD-1 or PD-L1/L2, such as nivolumab, pembrolizumab, and atezolizumab, have been developed and used in clinical trials (1). Furthermore, tumor immunotherapy based on the PD-1/PD-L1/L2 immune checkpoint blockade has demonstrated considerable efficacy Original Article

Mutation of PD-1 immune receptor tyrosine-based switch motif (ITSM) enhances the antitumor activity of cytotoxic T cells